Login / Signup

Cost-effectiveness analysis of 20-valent pneumococcal conjugate vaccine for routine pediatric vaccination programs in Japan.

Masayoshi ShinjohKanae TogoTomoyuki HayamizuNaohiro YonemotoJunko MoriiJohnna E PerdrizetKazumasa Kamei
Published in: Expert review of vaccines (2024)
As a pediatric vaccine, PCV20 was dominant over PCV13 regardless of the study perspective.
Keyphrases
  • public health
  • clinical practice
  • cancer therapy
  • young adults
  • childhood cancer